Literature DB >> 28936389

Disease Progression Modeling: Key Concepts and Recent Developments.

Sarah F Cook1,2, Robert R Bies1,2,3.   

Abstract

Disease modeling involves the use of mathematical functions to describe quantitatively the time course of disease progression. In order to characterize the natural progression of disease, these models generally incorporate longitudinal data for some biomarker(s) of disease severity or can incorporate more direct measures of disease severity. Disease models are also often linked to pharmacokinetic-pharmacodynamic models so that the influence of drug treatment on disease progression can be quantified and evaluated. Regulatory agencies have embraced disease progression models as powerful tools that can be used to improve drug development productivity. This article provides a brief overview of key concepts in disease progression modeling followed by illustrative examples from models for Alzheimer's disease. Finally, recent novel applications in which disease progression models have been linked to cost-effectiveness analysis and genomic analysis are described.

Entities:  

Keywords:  clinical pharmacology; disease progression; drug development; modeling and simulation; pharmacometrics

Year:  2016        PMID: 28936389      PMCID: PMC5602534          DOI: 10.1007/s40495-016-0066-x

Source DB:  PubMed          Journal:  Curr Pharmacol Rep        ISSN: 2198-641X


  54 in total

Review 1.  The FDA critical path initiative and its influence on new drug development.

Authors:  Janet Woodcock; Raymond Woosley
Journal:  Annu Rev Med       Date:  2008       Impact factor: 13.739

2.  Understanding placebo responses in Alzheimer's disease clinical trials from the literature meta-data and CAMD database.

Authors:  Kaori Ito; Brian Corrigan; Klaus Romero; Richard Anziano; Jon Neville; Diane Stephenson; Richard Lalonde
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

3.  Longitudinal data analysis for genetic studies in the whole-genome sequencing era.

Authors:  Zheyang Wu; Yijuan Hu; Phillip E Melton
Journal:  Genet Epidemiol       Date:  2014-09       Impact factor: 2.135

4.  Development of a rating scale for primary depressive illness.

Authors:  M Hamilton
Journal:  Br J Soc Clin Psychol       Date:  1967-12

5.  2015 Alzheimer's disease facts and figures.

Authors: 
Journal:  Alzheimers Dement       Date:  2015-03       Impact factor: 21.566

6.  Modelling the natural history of Huntington's disease progression.

Authors:  W L Kuan; A Kasis; Y Yuan; S L Mason; A S Lazar; R A Barker; J Goncalves
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-12-16       Impact factor: 10.154

7.  Disease progression meta-analysis model in Alzheimer's disease.

Authors:  Kaori Ito; Sima Ahadieh; Brian Corrigan; Jonathan French; Terence Fullerton; Thomas Tensfeldt
Journal:  Alzheimers Dement       Date:  2009-07-09       Impact factor: 21.566

8.  Development of a unified clinical trial database for Alzheimer's disease.

Authors:  Jon Neville; Steve Kopko; Steve Broadbent; Enrique Avilés; Robert Stafford; Christine M Solinsky; Lisa J Bain; Martin Cisneroz; Klaus Romero; Diane Stephenson
Journal:  Alzheimers Dement       Date:  2015-02-09       Impact factor: 21.566

9.  Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine.

Authors:  N H Holford; K E Peace
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

10.  Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin.

Authors:  J G C van Hasselt; A Gupta; Z Hussein; J H Beijnen; J H M Schellens; A D R Huitema
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-06-30
View more
  12 in total

1.  Does transition of urinary incontinence from one subtype to another represent progression of the disease?

Authors:  Vatché A Minassian; Xiaowei Yan; Anna L Pilzek; Raisa Platte; Walter F Stewart
Journal:  Int Urogynecol J       Date:  2018-03-13       Impact factor: 2.894

2.  Modeling Disease Progression Trajectories from Longitudinal Observational Data.

Authors:  Bum Chul Kwon; Peter Achenbach; Jessica L Dunne; William Hagopian; Markus Lundgren; Kenney Ng; Riitta Veijola; Brigitte I Frohnert; Vibha Anand
Journal:  AMIA Annu Symp Proc       Date:  2021-01-25

Review 3.  Role of Disease Progression Models in Drug Development.

Authors:  Jeffrey S Barrett; Tim Nicholas; Karim Azer; Brian W Corrigan
Journal:  Pharm Res       Date:  2022-04-11       Impact factor: 4.580

4.  Statistical Physics for Medical Diagnostics: Learning, Inference, and Optimization Algorithms.

Authors:  Abolfazl Ramezanpour; Andrew L Beam; Jonathan H Chen; Alireza Mashaghi
Journal:  Diagnostics (Basel)       Date:  2020-11-19

5.  A hierarchical Bayesian entry time realignment method to study the long-term natural history of diseases.

Authors:  Liangbo L Shen; Lucian V Del Priore; Joshua L Warren
Journal:  Sci Rep       Date:  2022-03-22       Impact factor: 4.996

6.  Solving the Evidence Interpretability Crisis in Health Technology Assessment: A Role for Mechanistic Models?

Authors:  Eulalie Courcelles; Jean-Pierre Boissel; Jacques Massol; Ingrid Klingmann; Riad Kahoul; Marc Hommel; Emmanuel Pham; Alexander Kulesza
Journal:  Front Med Technol       Date:  2022-02-24

7.  Emerging roles for clinical pharmacometrics in cancer precision medicine.

Authors:  Sujit Nair; Ah-Ng Tony Kong
Journal:  Curr Pharmacol Rep       Date:  2018-04-20

8.  Using medical claims database to develop a population disease progression model for leuprorelin-treated subjects with hormone-sensitive prostate cancer.

Authors:  Yixuan Zou; Fei Tang; Jeffery C Talbert; Chee M Ng
Journal:  PLoS One       Date:  2020-03-24       Impact factor: 3.240

9.  Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression.

Authors:  Salvatore D'Agate; Chandrashekhar Chavan; Michael Manyak; Juan Manuel Palacios-Moreno; Matthias Oelke; Martin C Michel; Claus G Roehrborn; Oscar Della Pasqua
Journal:  World J Urol       Date:  2020-12-18       Impact factor: 4.226

10.  Pharmacometrics meets statistics-A synergy for modern drug development.

Authors:  Yevgen Ryeznik; Oleksandr Sverdlov; Elin M Svensson; Grace Montepiedra; Andrew C Hooker; Weng Kee Wong
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.